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1. Introduction  
In this article, we provide an overview of the cytochrome P450 drug metabolism system, a 
major target for pharmacogenetics assays. We discuss briefly the major enzyme subfamilies 
and highlight some of the important members of each. We then delve into the currently 
available methodologies that are used for genotyping including single base (primer) 
extension, hybridization, ligation, and sequencing. The various methods have distinct 
requirements but all can be used for the interrogation of single nucleotide polymorphisms. 
These genetic differences may confer altered properties in the encoded enzymes including 
differences in the ability to metabolize drugs. Methods to identify such differences can help 
select subsets of patients who may or may not be able to effectively utilize particular 
medications. In such a manner, these techniques allow for the appropriate triage of patients 
to therapies that are targeted for their genotype, allowing for a tailored, individualized 
treatment regimen. Pharmacogenetic testing of this nature can help to usher in the era of 
personalized medicine. 
2. Genotypic variation in cytochrome P450s and effects on drug metabolism  
Adverse drug reactions are important causes of morbidity and mortality, and have been 
reported to result in significantly increased healthcare costs and longer hospital lengths of 
stay. Adverse drug reactions can result from comorbid diseases that affect drug 
metabolism such as renal or hepatic insufficiency, from drug-drug interactions, and from 
genetic factors affecting drug pharmacokinetics. Reduction of adverse drug reactions 
associated with comorbid conditions and drug-drug interactions is potentially achievable 
through increased awareness and reporting; however prevention of adverse drug 
reactions due to individual genetic differences requires a different approach – efficient 
and cost-effective determination of individual genotypic profiles of the enzymes involved 
in drug metabolism.  
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Drugs are metabolized through a series of reactions, the majority of which are carried out by 
cytochrome P450 (CYP), a monooxygenase superfamily of enzymes with over 60 members. 
The CYP genes are highly polymorphic in humans, with hundreds of single nucleotide 
polymorphisms (SNPs), insertions and deletions, and copy number variations described to 
date. These genetic polymorphisms give rise to different metabolic phenotypes: ultrarapid 
metabolizers (UM), extensive metabolizers (EM), intermediate metabolizers (IM) and poor 
metabolizers (PM). Individuals with the EM phenotype have two normal alleles and have 
normal metabolism; those with the IM phenotype have one defective allele and may have 
reduced drug metabolism; and those with the UM phenotype have gene duplications and 
have increased drug metabolism. The PM phenotype is characterized by two defective 
alleles, resulting in markedly decreased drug metabolism and in particular situations, 
higher levels of drugs and increased risk for adverse drug reactions.  
Of the many isoforms of CYP, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and 
CYP3A4, are responsible for the metabolism of the majority of clinically important drugs. 
(Table 1)  
 
 #SNPs 
Clinically significant alleles 
or %poor metabolizers 
Examples of substrates 
CYP1A2 >30 N.D. 
Caffeine, estradiol, clozapine, 
olanzapine, theophylline 
CYP2B6 >70 
CYP2B6*6: 15-40% Asians, 
>50% African-Americans 
Bupropion, methadone, 
ifosphamide, efavirenz, 
selegiline 
CYP2C9 >50 
CYP2C9*2: 8-19% 
Caucasians, 3.2% African-
Americans 
CYP2C9*3: 8.3% 
Caucasians, 3.3% Asians 
NSAIDs, angiotensin receptor 
blockers, sulfonylureas, 
warfarin 
CYP2C19 >30 
PM: 3-5% Caucasians, 15-
20% Asians 
Proton pump inhibitors, anti-
epileptics, clopidogrel 
CYP2D6 >100 
PM: <1% Asians, 2-5% 
African-Americans, 6-10% 
Caucasians 
Tricyclic antidepressants, SSRIs, 
opiods, anti-psychotics, 
tamoxifen, beta blockers, anti-
arrhythmics 
CYP2E1 10 N.D. Anesthetics 
CYP3A4 >30 N.D. 
Macrolide antibiotics, 
benzodiazepines, anti-
retrovirals, anti-histamines, 
calcium channel blockers, HMG 
CoA reductase inhibitors 
Table 1. Common CYP polymorphisms affect the metabolism of clinically important drugs. 
N.D.= not determined. 
CYP1A2 metabolizes several drugs including clozapine (used in the treatment of 
schizophrenia), theophylline (used to treat respiratory disorders such as COPD and asthma), 
and caffeine. Greater than 30 SNPs have been identified to date , but a genotype-phenotype 
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relationship has not yet been established. Similarly, a genotype-phenotype relationship has 
not yet been established for CYP2E1, a CYP protein responsible for the metabolism of most 
anesthetics.  
CYP2B6 is highly polymorphic (>70 SNPs) and metabolizes approximately 8% of clinically 
important drugs including the anti-retroviral drugs efavirenz and nevirapine, which are 
used in the treatment of HIV infection. The CYP2B6*6 allele, which is found commonly in 
Asians and African-Americans, results in decreased metabolism and response to efavirenz.  
Greater than 50 SNPs have been identified for CYP2C9, which metabolizes approximately 10% 
of all clinically prescribed medications. One of the most important drugs metabolized by 
CYP2C9 is warfarin, a widely used anticoagulant. CYP2C9*2 and CYP2C9*3 alleles which are 
relatively common in Caucasians (approximately 8%) have been implicated as playing a large 
role in the interindividual variation in the metabolism of this drug. These alleles have been 
demonstrated to reduce enzymatic activity in vitro, *2 by 70% and *3 by 30%, respectively.  
CYP2C19 plays a role in the metabolism of several drugs, but perhaps has been best studied 
for its role in the metabolism of proton pump inhibitors which are used to treat 
gastroesophageal reflux disorders. 3-5% of Caucasians and 15-20% of Asians are CYP2C19 
poor metabolizers. PMs have reduced metabolism of proton pump inhibitors, leading to 
increased plasma levels of drug and increased response to treatment. Recently, 2C19 has 
become popular because of its involvement in the metabolism of Plavix, an antiplatelet drug 
used to prevent strokes and heart attacks. Important alleles include *2 and *3 which reduce 
enzymatic activity, and *17 which produces an ultrarapid metabolizer phenotype. Of great 
interest, 2C19 shares homology with 2C9. In fact, >90% of the amino acid sequence is identical 
between these two isoforms. Despite their near identity at the amino acid level, the active site 
of the two enzymes differs, and thus accounts for the differences in substrate specificity. 
CYP2D6 is highly polymorphic with greater than 100 SNPs thus far characterized. These 
genetic polymorphisms play a significant role in affecting the metabolism of ~20% of 
clinically important drugs including anti-depressants, anti-psychotics, anti-arrhythmics, and 
beta blockers. These features make CYP2D6 an attractive target for pharmacogenetic assays. 
The PM phenotype is found in < 1% of Asians, 2-5% of African-Americans, and 6-10% of 
Caucasians. Interestingly, only six alleles of CYP2D6 account for >99% of the poor 
metabolizers in the Caucasian population (Roberts et al. 2006). Hence, a targeted approach 
to interrogate these six SNPs could provide a useful assay to identify such individuals in 
this limited cohort. 
The CYP3A family of isoforms are crucial drivers of drug metabolism in the liver. In fact, CYPs 
3A4 and 3A5 are responsible for 40-50% of all such activity. CYP3A4 metabolizes a large range 
of clinically important drugs, and over 30 SNPs have been described. However, no significant 
interindividual variability has yet been reported , suggesting that genetic variation may not 
play a large role in regulating CYP3A4 activity. Interestingly however, the *3 allele which 
results in a variant with a reduced metabolism phenotype is found in ~30% of Caucasians. The 
3A5 isoform is less well characterized but shares overlapping substrate specificity with 3A4. 
In summary, hundreds of SNPs have been identified within the multiple members of the 
SNP superfamily and other genes involved in drug metabolism, making these genes an 
important target for SNP genotyping in pharmacogenetics and personalized medicine. 
Various techniques for SNP genotyping are described in the following section.  
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3. SNP genotyping methods 
Many SNP genotyping strategies have been developed, ranging from small scale, low-
throughput approaches to interrogate one of few SNPs, to large scale, high-throughput 
approaches that can genotype hundreds of SNPs. Both small and large scale approaches 
have been applied for pharmacogenetics studies. These approaches generally detect SNP 
alleles using one of the following strategies: primer extension, hybridization, ligation, or 
sequencing.  
3.1 Single base (primer) extension 
Single base (primer) extension is a process that involves the use of a SNP probe with the 3’ 
end a single base upstream of the SNP of interest. The SNP probe is then extended by a 
single base, and the incorporated base is detected. Detection can be either through 
fluorescence, if a fluorophore is incorporated into the dideoxynucleotides and an 
appropriate detector is used, or can be done based on sizing of fragments if a size separation 
technique, such as mass spectrometry, is used. 
As an example, we have developed an assay using this technology to determine the 
genotype profile of genes affecting the metabolism of warfarin. Warfarin is a widely used 
anticoagulant. However, the combination of variable, genetically-based, individual 
responses to warfarin and a narrow therapeutic window with potentially serious 
complications, make this an ideal situation in which pharmacogenetics testing could be 
beneficial. As described above, the CYP2C9*2 and CYP2C9*3 alleles have been shown to 
be important in the metabolism of warfarin. In addition, warfarin inhibits Vitamin K 
epoxide reductase complex subunit 1 (VKORC1), an enzyme complex that reduces 
vitamin K 2,3 epoxide to its active form. Multiple SNPs have been identified in VKORC1, 
leading to either low-dose or high-dose phenotypes. VKORC1 polymorphisms, which are 
found commonly in many populations, have been estimated to account for approximately 
25% of the variability in warfarin dose requirement. Finally, gamma-glutamyl carboxylase 
(GGCX) is an enzyme that catalyzes the post-translational modification of vitamin K-
dependent proteins and has been reported to have a modest effect on warfarin 
metabolism. 
Four SNPs for these genes were examined simultaneously in a multiplexed assay. Genomic 
DNA was isolated from whole blood and the region of interest was amplified by PCR. SNP 
primers (each of different length) were designed with the sequence ending one nucleotide 
upstream of the SNP of interest. The primer was then extended a single base with a 
fluorescently labelled dideoxynucleotide terminator (ddNTP). The reaction product was 
then separated by capillary electrophoresis and analyzed. (Fig 1)  
This method has several advantages. It is an accurate procedure that can be performed 
with minimal hands-on effort. It lends itself to custom design and is flexible in  
that oligonucleotide probes used to detect SNPs of interest can be added or removed 
quickly from an existing panel. In our hands, this method gave results that were 100% 
concordant with traditional sequencing results. This method has the additional benefit of 
a short turnaround time- the entire analysis may be performed in less than 24 hours, the 
majority of which is needed for incubation steps and for the automated electrophoretic 
separation.  
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Fig. 1. Detection of SNPs by single base primer extension. Blood is collected from a patient 
and genomic DNA is isolated from lymphocytes. A multiplex PCR reaction is performed to 
amplify DNA fragments containing the SNP of interest. This is followed by a multiplex SNP 
reaction whereby oligonucleotides ending one base pair upstream of the SNP of interest are 
added and then extended with nucleotide terminators. In the case of capillary 
electrophoresis, detection is based on fluorescence whereby the ddNTPs are tagged with 
various fluorophores. In contrast, for mass spectrometry detection is based on accurate 
sizing of modified nucleotide terminators. 
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In addition to the assay described above for assessing warfarin metabolism, we have 
successfully used the same approach to interrogate 8 SNPs of CYP2D6. As described in the 
previous section, CYP2D6 is highly polymorphic and plays a role in the metabolism of 
approximately one-fourth of clinically important drugs. We sought to interrogate these SNPs 
to characterize the PM phenotype. One limitation of this approach (and capillary 
electrophoresis in general) is in the resolving capacity of this technique, which under our 
conditions is ~2 nt. In our procedure, we are resolving and visualizing oligonucleotides for 
SNP interrogation in a window from 10-95 nt, the maximum number of fragments that can be 
resolved is ~12. This resolving capacity is inherent to the capillary electrophoresis 
methodology and commercial analyzers of which several are available, all share this limitation. 
A similar approach can be used to multiplex a larger number of SNPs, and can thus 
overcome the limitations described above. Such a genotyping approach needs to exploit 
methods that are of higher resolution (relative to capillary electrophoresis), such as mass 
spectrometry. Using this technique, genomic DNA is isolated, the region of interest is 
amplified by PCR, and SNP primers are hybridized, as described above. These SNP primers 
are extended by a single base with unlabelled dideoxynucleotide terminators.  
The SNP allele is then detected by the mass of the extension product, as a function of the 
time required to traverse the time-of-flight tube. (Fig 1) We have recently used this 
technique to interrogate 11 SNPs simultaneously from a single sample. This technique is 
(theoretically) capable of resolving up to 35-40 SNPs in one well, and thus a greater number 
of SNPs can be interrogated (relative to capillary electrophoresis), whether they reside in 
one gene or many genes. Such a methodology is ideal when the number of SNPs of interest 
is within these parameters.  
Several commercial platforms offer larger scale SNP genotyping using single base extension 
as an approach. The MassARRAY system (Sequenom), an example of a mass spectrometric 
based platform as described above, can interrogate ~35-40 SNPs simultaneously. The 
SNPstream assay (Beckman Coulter) is able to interrogate either 12 or 48 SNPs 
simultaneously in a 384-well plate. A fluorescently labelled nucleotide is added to a tagged 
SNP probe by single base extension. Each well of the 384-well plate contains tagged 
oligonucleotides at specific positions within the well. These tagged oligonucleotides are 
complementary to one of the 12 or 48 tagged SNP probes. The genotype of the SNP is 
identified by determination of the position of fluorescence in the well.  
3.2 Hybridization-based approaches 
Hybridization-based approaches for SNP genotyping depend on stringent hybridization 
conditions (conducive to the ability or inability to form Watson-Crick base pairs) as a means to 
distinguish one or more alleles. As compared to single base primer extension, hybridization 
assays are sensitive to variations on length and sequence of both probe and target 
oligonucleotides. Similar to primer extension, hybridization assays can also interrogate many 
SNPs simultaneously within the same sample. For example, the Affymetrix GeneChip is an 
array of oligonucleotides that allows genome-wide interrogation of SNPs.  
In hybridization-based approaches, genomic DNA is isolated, regions of interest are 
amplified, cleaved, and then tagged, for example with biotin. The tagged products are 
subsequently hybridized under stringent conditions to allele-specific oligonucleotides on a 
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solid matrix, such as a bead or array. These allele-specific oligonucleotides differ by only 
one or few bases, and correspond to the various alleles of the DNA fragment of interest. The 
reaction is performed under conditions whereby mismatched targets, i.e. those that do not 
hybridize perfectly, can be washed away. This leaves only the stably hybridized DNA 
fragments, i.e. those that have a perfect match to their corresponding target, that are 
fluorescently labelled. Subsequent detection of the fluorescent signal allows for the 
determination of the SNP genotype. The specificity of the assay can be increased by using 
multiple probes for each SNP allele (Figure 2). 
 
 
Fig. 2. Detection of SNPs by hybridization. Blood is collected from a patient and genomic 
DNA is isolated from lymphocytes. A PCR reaction is performed to amplify and tag DNA 
fragments containing the SNP of interest. Tagged DNA fragments are hybridized to SNP 
probes bound to a solid matrix, and mismatched fragments are washed away. Hybridized 
fragments are fluorescently labelled and detected to determine the SNP genotype.  
Dynamic allele-specific hybridization (DASH) is another assay that utilizes differential 
hybridization for SNP genotyping. In DASH, genomic DNA is isolated, and the region of 
interest is amplified using a biotinylated primer. The biotin tag allows for the attachment of 
a single stranded DNA fragment to a bead. This is then hybridized with a SNP-specific 
oligonucleotide. Now, a fluorescent molecule that intercalates into the double-stranded 
DNA is added, and the fluorescence signal is measured over an increasing temperature 
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gradient. A melting curve can thus be established. (Fig 3) A complete match between the 
genomic DNA and the SNP-specific oligonucleotide results in the expected melting 
temperature curve, whereas mismatches result in a curve showing lowered melting 
temperatures. This technique was used in a study of 13 SNPs in the adiponectin gene which 
has been linked to type 2 diabetes.  
 
 
Fig. 3. Dynamic allele-specific hybridization (DASH). Blood is collected from a patient and 
genomic DNA is isolated from lymphocytes. A PCR reaction is performed to amplify and 
tag DNA fragments containing the SNP of interest. The DNA fragment is attached to a 
streptavidin bead, and is hybridized to a SNP probe. A fluorescent intercalating DNA dye is 
added, and a melting curve is determined. A mismatch (dashed line) will result in a lower 
melting temperature. 
A unique take on the use of hybidization for SNP genotyping involves the use of molecular 
beacons. A molecular beacon is an oligonucleotide hairpin with a fluorophore at one end and a 
fluorescence quencher at the other end with a sequence complementary to the SNP allele nested 
in the middle. In the unbound state, no fluorescent signal will be emitted as the fluorophore and 
the fluorescence quencher are in close proximity at the stem of the hairpin structure. When the 
molecular beacon hybridizes with a perfect match to a genomic DNA fragment, the hairpin 
structure of the molecular beacon is linearized, separating the fluorophore and the fluorescence 
quencher, allowing fluorescence signal to be emitted (Figure 4). 
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Fig. 4. Interrogation of SNPs using molecular beacons. Blood is collected from a patient and 
genomic DNA is isolated from lymphocytes. A PCR reaction is performed to amplify DNA 
fragments containing the SNP of interest. The DNA fragment is hybridized to a molecular 
beacon. When the molecular beacon is not bound to the DNA fragment, the fluorophore and 
fluorescence quencher are held in close proximity to each other and no fluorescence signal is 
emitted. When the molecular beacon hybridizes with the DNA fragment, the flurophore and 
fluorescence quencher are separated and fluorescence is emitted.  
The TaqMan (Applied Biosystems) assay is a widely used assay that utilizes hybridization to 
determine SNP genotypes. This assay takes advantage of the 5’ nuclease activity of Taq 
polymerase to detect SNP alleles. In this assay, the region of interest is amplified by PCR. In 
addition to the forward and reverse primers, an allele-specific probe is also hybridized 
under stringent conditions to the template DNA. The allele-specific probe has a fluorophore 
at the 5’ end and a fluorescence quencher at the 3’ end. When the allele-specific probe 
perfectly complements the template DNA, it is stably bound, whereas when there is a 
mismatch, the probe will not hybridize stably with the template DNA and will not be a 
substrate for the 5’ nuclease activity of Taq polymerase. When Taq polymerase reaches the 
allele-specific probe as it extends DNA from the primer, the 5’ fluorophore is released by the 
5’ nuclease activity of Taq polymerase, and the probe is displaced. Release of the 5’ 
fluorophore separates the fluorophore from the 3’ fluorescence quencher, allowing 
fluorescence to be emitted and subsequently measured (Figure 5). The Taqman assay was 
recently used to interrogate 121 SNPs to analyze Y-chromosome variation in 264 samples.  
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Fig. 5. SNP interrogation utilizing the 5’ nuclease activity of Taq polymerase. Blood is 
collected from a patient and genomic DNA is isolated from lymphocytes. A DNA fragment 
containing the SNP of interest is amplified by PCR in the presence of an allele-specific probe 
labelled with a fluorophore at one end, and with a fluorescence quencher at the other end. 
When the allele-specific probe complements the DNA, the 5’ nuclease activity of Taq 
polymerase will release the fluorophore, and fluorescence signal will be detected.  
3.3 Ligation-based approaches 
The ligation-based approach to interrogate SNPs exploits the ability of DNA ligase to ligate two 
adjacent oligonucleotides bound to a template DNA. In this assay, two oligonucleotides are 
required; an allele-specific oligonucleotide which has its 3' end complementary to the SNP 
nucleotide to be interrogated, and a second oligonucleotide with its 5' end designed to anneal 
immediately adjacent to the 3' end of the first oligonucleotide. Both oligonucleotides are 
hybridized to the target DNA. DNA ligase is then added to the reaction. Only if the 3' end of the 
first oligonucleotide is indeed complementary to the SNP allele, will ligation occur, as DNA 
ligase is sensitive to 3’ mismatches. The ligated and unligated products are of different sizes and 
can thus be detected using a separation technique, for example capillary electrophoresis or mass 
spectrometry analysis. This approach can also be scaled up for high throughput analysis. (Fig 6) 
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Fig. 6. SNP allele detection by ligation. Blood is collected from a patient and genomic DNA 
is isolated from lymphocytes. A DNA fragment containing the SNP of interest is amplified 
by PCR. Two oligonucleotides are annealed to the DNA fragment, flanking the SNP site to 
be interrogated. If the allele-specific oligonucleotide is complementary to the SNP allele, 
DNA ligase will be able to ligate the oligonucleotides, and the ligated product can be 
detected by capillary electrophoresis or mass spectrometry.  
The oligonucleotide ligation and capillary electrophoresis method is used in the SNPlex 
assay (Applied Biosystems), a platform which allows multiplexing for the detection of 
multiple SNPs simultaneously. The SNPlex assay has been used in multiple studies; in a 
recent study it was used to detect SNPs in 528 members of families with sarcoidosis. 
3.4 Sequencing based strategies: Pyrosequencing and other next generation 
sequencing methods 
Conventional capillary electrophoresis based Sanger sequencing was developed in the (late) 
1970s and became widely adopted thereafter. It revolutionized life science research in the 
subsequent years by providing a critical tool that was fundamental in the elucidation of 
genetic sequence information. Despite this, the technology suffers from limitations in speed, 
resolution, throughput and scalability 
Next-generation sequencing technologies have recently been developed and have made 
possible cost-efficient, high-throughput sequencing, that can overcome these drawbacks. An 
example of next-generation sequencing is pyrosequencing, a sequencing-by-synthesis 
technique. The pyrosequencing technique sequences approximately 250 bases per read. In 
pyrosequencing, each added base is detected in real-time by fluorescence. Specifically, 
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genomic DNA is isolated, and the region of interest is amplified by PCR. A sequencing 
primer is then annealed to the template DNA, and the reaction components are added: DNA 
polymerase, ATP sulfurylase, luciferase, apyrase, adenosine 5’ phosphosulfate (APS), and 
luciferin. One of four deoxynucleotide triphosphates (dTTP, dCTP, dGTP, or dATPS) is 
then added (dATPS is used in place of dATP as it can be incorporated by DNA 
polymerase, but is not a substrate for luciferase). If the added dNTP is complementary to the 
template DNA, the dNTP is incorporated by DNA polymerase, releasing pyrophosphate 
(PPi). The released PPi is converted to ATP by ATP sulfurylase with adenosine 5’ 
phosphosulfate as a substrate. The ATP serves to drive the conversion of luciferin to 
oxyluciferin by the luciferase enzyme. Oxyluciferin generates visible light proportional to 
the amount of ATP. This visible light is measured and used to determine if a dNTP was 
incorporated, and if so, the number of dNTPs added. The unincorporated dNTPs and ATP 
is degraded by apyrase. This cycle of reactions is repeated with the next dNTP. By this 
process of sequential addition of dNTPs, the sequence can be determined. (Fig 7) 
 
Fig. 7. Pyrosequencing. Blood is collected from a patient and genomic DNA is isolated from 
lymphocytes. A DNA fragment containing the SNP of interest is amplified by PCR. A 
sequencing primer is added, as are the sequencing reaction components: DNA polymerase, 
one of four dNTPs (dTTP, dCTP, dGTP, or dATPS). If the nucleotide is incorporated, PPi is 
released, which is then converted by ATP sulfurylase to ATP. The ATP drives the 
conversion of luciferin to oxyluciferin by luciferase. Oxyluciferin generates visible light 
proportional to the amount of ATP. 
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A high-throughput application of pyrosequencing, termed 454 pyrosequencing, was 
developed in 2005 by 454 Life Sciences. In this technique, the target DNA is attached to a 
bead and placed in a picoliter-sized well of a fiberoptic slide (containing 1.6 million wells). 
The substrates for the pyrosequencing reaction are added to the wells in waves via a flow-
chamber, the light signal is detected, and the sequence is determined. This parallelized 
pyrosequencing technology allows the determination of mega- to gigabase amounts of DNA 
in a fast and cost-efficient manner.  
Illumina (Solexa) sequencing is another next-generation sequencing technology that has 
recently been developed for high-throughput sequencing. DNA is sequenced by repeated 
cycles of single base extension. As in standard single base extension, DNA is extended a 
single base with a fluorescently labelled nucleotide terminator. The nucleotide terminator in 
this case is not a dideoxynucleotide; instead it is a modified, reversible terminator. The 
identity of the incorporated base is determined by detection of fluorescence. Next, the 
flurophore is removed and the terminator is reversed, and the cycle of single base extension 
is repeated. In this manner, approximately 75 bases can be read at a time.  
A third important next-generation sequencing technology is SOLiD sequencing (Sequencing 
by Oligonucleotide Ligation and Detection), a technology developed by Applied 
Biosystems. Rather than utilizing a polymerase, this technology utilizes an elegant system of 
hybridization and ligation steps to determine the sequence of target DNA. In brief, DNA is 
attached to a flow cell and is hybridized and ligated to one of a set of fluorescently labelled 
probes. The fluorescence is detected, then cleaved and the process is repeated to extend the 
sequence. A combination of repeated hybridization and ligation steps and use of primers 
with different offsets allows not only the sequence to be determined, but also provides a 
“two-base” read to improve accuracy. This technology can provide sequence data of 
approximately 50 bases with each individual read. This individual sequencing reaction is 
performed across millions of templates in a massively parallel fashion. Thus, in a rapid 
manner, large stretches of DNA can be sequenced spanning entire genomes. In fact, the 
amount of DNA sequence data that is generated is staggering, exceeding hundreds of 
gigabytes of information from a single run. A single instrument today can generate more 
information in a 24 hour period than was possible using multiple instruments with standard 
technology operating over a decade, in the 1980s, 1990s, and even in the 2000s.  
3.5 Other SNP genotyping methods 
The Invader assay (Third Wave Technologies) utilizes the ability of Flap endonuclease (FEN) 
to cleave specific DNA structures to determine SNP alleles. Flap endonuclease is a 5’ nuclease 
that recognizes DNA structures with a single stranded 5’ overhang, or flap. Flap endonuclease 
will cleave DNA at the junction of the single and double stranded DNA. In this assay, genomic 
DNA is isolated and the region of interest is amplified by PCR. Two probes are hybridized to 
the target DNA: an Invader oligonucleotide and an allele-specific oligonucleotide. The Invader 
oligonucleotide is designed to anneal with its 3’ end immediately upstream to the SNP site. 
The allele-specific oligonucleotide, which has a 5’ fluorophore and a 3’ fluorescence quencher, 
anneals to the SNP site and to the downstream sequence. In addition, the allele-specific 
oligonucleotide has additional 5’ sequence not complementary to upstream sequence that 
extends from the bound DNA, forming a structure recognized by FEN. Cleavage of the allele-
specific oligonucleotide by FEN separates the 5’ fluorophore from the 3’ fluorescence 
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quencher, and allows fluorescence to be emitted. If the allele-specific oligonucleotide does not 
complement the SNP site exactly, the resulting structure is not recognized by Flap 
endonuclease and no fluorescence signal will be detected. (Fig 8) 
 
Fig. 8. Invader assay for SNP interrogation. Blood is collected from a patient and genomic 
DNA is isolated from lymphocytes. A DNA fragment containing the SNP of interest is 
amplified by PCR. An Invader probe (blue) and an allele-specific probe labelled with a 
flurophore and a fluorescence quencher are hybridized to the DNA fragment. FEN 
recognizes the resulting structure and cleaves it, releasing the fluorophore.  
The Invader assay was successfully used (in conjunction with other SNP genotyping 
methods) to genotype 122 SNPs in 9 candidate genes associated with diabetes. In a study by 
Ozaki et al., a multiplexed Invader assay was used to interrogate 92,788 SNPs from 94 
individuals in a genome-wide association study. 
4. Considerations in the selection of the appropriate SNP genotyping tool 
Several factors merit consideration and are important for the judicious selection of an 
appropriate SNP genotyping assay. Accuracy, reliability, and establishment of quality 
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control are intermingled and readily apparent as important factors. These elements are 
critical to the development of a robust assay and the validation of such. The accuracy and 
reliability of results is paramount since these data are used to inform clinical decision 
making by allowing for optimized selection of therapy for the patient. The inclusion and 
establishment of an appropriate quality control paradigm ensures the integrity of reagents, 
test conditions, and experimental and technical workflow. These features form the basis of, 
and are a prerequisite to, generating an accurate and reliable result. 
There are additional factors that will affect more widespread adoption of these assays and 
make individualized patient therapy available and accessible to most patients. Such 
considerations include: speed, automation, customizability, and the requirement for 
specialized equipment and /or technical training. These set of factors deal with the logistics 
in operationalizing the implementation of such assays. 
The speed at which results are obtained and the test’s ease of use can directly affect the 
clinical utility of the assay and further dictate where the assay is performed and who can 
conduct testing (regulatory requirements differ by country, and within the United States 
they may also differ by state, e.g. New York). For example, under certain conditions it may 
be favourable for testing to be conducted by a healthcare provider in an outpatient setting 
where results are immediately used to make treatment decisions. If an assay is fairly 
straightforward & easy to use and the chances of obtaining an accurate result are high, it 
may be advantageous to perform outside the clinical laboratory. On the contrary, it may be 
beneficial for testing to be sent to a centralized laboratory and performed by a trained, 
licensed technologist. This is the ideal situation for a higher complexity test. However, in 
this situation, results may not be immediately available and thus there will be a delay in 
using the information to change clinical management of the patient.  
Assays in which little hands-on effort is required and can be automated will increase speed, 
throughput, and will help to reduce errors. In cases where numerous SNPs are interrogated, 
a single, multiplexed reaction allows for the simultaneous investigation of several SNPs, 
reducing time and cost. The number of SNPs identified and characterized as playing a role 
in drug metabolism to date has been a relatively manageable size; however, as more SNPs 
are identified, both multiplexed and high-throughput assays could further reduce costs 
Customized assays are advantageous in that they are designed to answer focused questions, 
and can be tailored to specific patient populations. In addition, they are flexible and can be 
rapidly changed as new clinically significant SNPs are identified and need to be 
incorporated. A requirement for specialized training and/or equipment may slow 
widespread adoption of a SNP genotyping assay but is necessary for conducting high 
complexity testing of this nature. Finally, cost also can play an important role, particularly in 
an environment of increasing healthcare expenditures. In recent years, pharmacogenetic 
testing (and other molecular diagnostics assays) have come under greater scrutiny and the 
debate over appropriate reimbursement scales by insurance payers continues.  
The methodologies described in the previous section have all been used successfully to 
genotype SNPs, however they have different advantages and limitations that factor into 
their usefulness in individualized SNP genotyping assays. (Table 2) The ideal assay would 
combine the advantages of each methodology, and eliminate the common requirement for 
either large amounts of DNA or for an initial PCR step. New technologies that would 
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increase sensitivity or reduce the need for multiplexed PCR would be necessary to make the 
simultaneous interrogation of hundreds or thousands of SNPs faster and more cost-
effective.  
 
Methodology 
Multiplexed 
assays? 
High-
throughput 
assays? 
Advantages Limitations 
Single base 
(primer) 
extension 
Yes Yes 
High accuracy of 
incorporation by 
DNA polymerase 
Multiple steps for 
detection/ 
separation 
Hybridization More difficult Yes 
Widely available; 
not dependent on 
enzymatic 
reaction 
Requirement for 
optimization of 
probes and 
hybridization 
conditions 
Ligation Yes Yes 
High specificity of 
DNA ligase 
Multiple steps for 
detection/ 
separation 
Sequencing More difficult Yes 
Sequencing of 50-
250 bases; speed 
Specialized 
equipment 
required 
Table 2. Comparison of SNP genotyping methodologies.  
5. Conclusions 
Multiple genetic differences between individuals have been described in the Cytochrome 
P450 family of drug metabolizing enzymes. These genetic differences may confer altered 
properties including differences in the ability to metabolize drugs. Methods to identify such 
differences can help select subsets of patients who may or may not be able to effectively 
utilize particular medications. Several widely used methods with differing approaches and 
advantages have been highlighted above. Further technological advances will help these 
technologies become more widely adopted. These techniques allow for the appropriate 
triage of patients to therapies that are targeted for their genotype, allowing for a tailored, 
individualized treatment regimen. Pharmacogenetic testing of this nature will help to usher 
in this new era of personalized medicine. 
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